Loquen XR 300 mg tablete s produljenim oslobađanjem
| Name | Loquen XR 300 mg tablete s produljenim oslobađanjem |
|---|---|
| Marketing Authorisation Number | HR-H-899405923 |
| Active Substance | kvetiapinfumarat |
| Composition | svaka tableta sadrži 300 mg kvetiapina u obliku kvetiapinfumarata |
| Pharmaceutical Form | tableta s produljenim oslobađanjem |
| Manufacturer | Teva Gyogyszergyar Zrt., Debrecen, Mađarska
Pharmachemie B.V., Haarlem, Nizozemska Teva Czech Industries s.r.o., Opava-Komarov, Češka Teva Operations Poland Sp. z o.o., Krakow, Poljska Teva Pharma S.L.U., Zaragoza, Španjolska Merckle GmbH, Blaubeuren, Baden-Wuerttemberg, Njemačka Adamed Sp. z o.o., Czosnow, Poljska |
| Marketing Authorisation Holder | Pliva Hrvatska d.o.o., Prilaz baruna Filipovića 25, Zagreb, Hrvatska |
| Marketing Authorisation Date | 08.05.2019 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/18-02/164 |
| Registration Number | 381-12-01/38-19-03 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | N05AH04 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Educational materials for healthcare professionals |
Podsjetnik o važnosti nadziranja, verzija 3 |
